The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies—Beyond BRAF Mutant Detection

SIMPLE SUMMARY: Circulating tumour DNA (ctDNA) has been shown to be an informative biomarker in melanoma. Here we analysed plasma ctDNA in a real-world metastatic melanoma cohort. We found the kinetics of ctDNA decline are delayed in patients treated with immunotherapy compared to those receiving MA...

Descripción completa

Detalles Bibliográficos
Autores principales: Marsavela, Gabriela, Johansson, Peter A., Pereira, Michelle R., McEvoy, Ashleigh C., Reid, Anna L., Robinson, Cleo, Warburton, Lydia, Khattak, Muhammad A., Meniawy, Tarek M., Amanuel, Benhur, Millward, Michael, Hayward, Nicholas K., Ziman, Melanie R., Gray, Elin S., Calapre, Leslie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765660/
https://www.ncbi.nlm.nih.gov/pubmed/33339135
http://dx.doi.org/10.3390/cancers12123793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765660/
https://www.ncbi.nlm.nih.gov/pubmed/33339135
http://dx.doi.org/10.3390/cancers12123793

Ejemplares similares